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ABSTRACT
Objectives In England, healthcare policy advocates 
specialised age- appropriate services for teenagers 
and young adults (TYA), those aged 13 to 24 years at 
diagnosis. Specialist Principal Treatment Centres (PTC) 
provide enhanced TYA age- specific care, although many 
still receive care in adult or children’s cancer services. We 
present the first prospective structured analysis of quality 
of life (QOL) associated with the amount of care received 
in a TYA- PTC
Design Longitudinal cohort study.
Setting Hospitals delivering inpatient cancer care in 
England.
Participants 1114 young people aged 13 to 24 years 
newly diagnosed with cancer.
Intervention Exposure to the TYA- PTC defined as patients 
receiving NO- TYA- PTC care with those receiving ALL- TYA- 
PTC and SOME- TYA- PTC care.
Primary outcome Quality of life measured at five time 
points: 6, 12, 18, 24 and 36 months after diagnosis.
Results Group mean total QOL improved over time for 
all patients, but for those receiving NO- TYA- PTC was 
an average of 5.63 points higher (95% CI 2.77 to 8.49) 
than in young people receiving SOME- TYA- PTC care, and 
4·17 points higher (95% CI 1.07 to 7.28) compared with 
ALL- TYA- PTC care. Differences were greatest 6 months 
after diagnosis, reduced over time and did not meet the 
8- point level that is proposed to be clinically significant. 
Young people receiving NO- TYA- PTC care were more likely 
to have been offered a choice of place of care, be older, 
from more deprived areas, in work and have less severe 
disease. However, analyses adjusting for confounding 
factors did not explain the differences between TYA 
groups.
Conclusions Receipt of some or all care in a TYA- PTC 
was associated with lower QOL shortly after cancer 
diagnosis. The NO- TYA- PTC group had higher QOL 
3 years after diagnosis, however those receiving all or 
some care in a TYA- PTC experienced more rapid QOL 
improvements. Receipt of some care in a TYA- PTC 
requires further study.
INTRODUCTION
Cancer in teenagers and young adults (TYA) 
is uncommon. Despite this, cancer in young 
people aged 15 to 29 years at diagnosis 
accounts for an estimated 350 000 new inci-
dent cases and incidence rates are rising.1 
Lower survival rates than younger children 
in several common cancer types2 have fuelled 
many international initiatives aimed to 
improve outcomes and well- being.3 4 In partic-
ular, the need for specialist age- appropriate 
care and environments are advocated as a 
critical component of good cancer care for 
TYA.5–9 However, the effect on clinical and 
patient- reported outcomes associated with 
age- appropriate care are yet to be described.10
Strengths and limitations of this study
 ► We present the first national evaluation of a model of 
care which aims to improve outcomes for teenagers 
and young adults with cancer.
 ► We were able to quantify where young people re-
ceived care through nationally collated hospital 
activity data so we could objectively assign young 
people to a group representing the model of care 
received.
 ► Analysis of longitudinal data for 3 years after diagno-
sis was adjusted for multiple confounding variables, 
identified from a conceptual model of patient ex-
perience, which underpinned data collection in the 
study.
 ► The measure quantifying where care was received 
was based on the assumption that all teenage and 
young adult Principal Treatment Centres provided 
equivalent facilities and care.
 ► The cohort comprises 20% of young people diag-
nosed with cancer during the time period, which 
could impact on the generalisability of the results.
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Distinct cancer service provision for TYA began in the 
UK in the 1990s.11 This was initiated by clinician and 
patient advocacy, promoting principles which responded 
to young people’s reports of care that frequently lacked 
support for their priorities of progress towards normal 
life goals and for care to be delivered alongside others of 
a similar age and by professionals who understood young 
people.' .12 Specialised services for young people being 
treated for cancer within the National Health Service 
(NHS) have been mandated in England since 2005 by 
the National Institute for Health and Clinical Excellence 
(NICE) guidance.3 The guidance identified that young 
people’s needs may be poorly met in children’s and older 
adult services working in isolation from each other,4 and 
that TYA- specific places of treatment and care may be 
key to achieving better outcomes for young people with 
cancer9 due in part to the distinct impact of cancer on 
young people’s well- being, such as in the physical, psycho-
social and developmental domains.13
The delivery of cancer care for TYA in England
Healthcare in England is in the main, publicly funded 
through the NHS providing universal comprehensive 
healthcare to all citizens. ‘The service is configured 
to improve, prevent, diagnose and treat physical and 
mental health problems with equal regard.’14 Secondary 
care is delivered in NHS Trusts. Each Trust has its own 
Chief Executive and leadership team and while they are 
governed by central NHS legislation, each Trust works as 
an independent entity. The configuration and delivery 
of services is therefore unique to each Trust, ensuring 
that each geographical region in England has access to 
essential healthcare services. Healthcare delivery by a 
Trust could be provided in a single hospital providing all 
the required services or it could be a merger of multiple 
hospitals in the geographical area each providing specific 
services (for example: https://www. uclh. nhs. uk/ OurSer-
vices/ OurHospitals/ Pages/ Home. aspx).15
The model of specialised TYA cancer care implemented 
from 2005 focussed on 13 TYA Principal Treatment 
Centres (TYA- PTC) in England. These were based in 
13 different Trusts, selected to complement the existing 
services delivered in children’s cancer units (aged up 
to 16 years in the main but local variation would accept 
older teenagers) and adult cancer services from 18 years 
onward. The TYA- PTCs were funded to deliver specialist 
care, which included the same standard of cancer care 
as the children and adult units but care was enhanced by 
the addition of age- appropriate environments and multi-
disciplinary teams experienced in working with TYA. For 
example, providing education and career support to 
enable TYA to continue with education and employment 
at a critical time in their lives; nurse specialists who were 
skilled at discussing challenging subjects (sex, fertility, 
drug and alcohol use); space to interact with other TYA 
with cancer to promote normal development and youth 
support coordinators who provide youth support and 
facilitate peer- to- peer activities (see Morgan et al7 for 
examples of what is included in a TYA unit).
The location of the TYA- PTCs were chosen based on a 
number of factors, including existing established service, 
geographical location and other cancer services avail-
able. The guidance directed that TYA aged 16 to 18 years 
must be treated in a TYA- PTC, while young adults aged 
19 to 24 years were to be offered the choice to receive 
care in a TYA- PTC or a local cancer unit that could 
provide their cancer treatment and some aspects of age- 
appropriate care. There was variation in the lower age 
of admission in TYA- PTCs based on history and avail-
ability of other services locally so this resulted in TYA 
aged 13 to 16 being treated in a children’s cancer unit 
or TYA- PTC and those aged 17 to 24 could be admitted 
to a TYA- PTC or adult cancer unit. By 2010, about two- 
thirds of those aged 15 to 18 years and one- third of 19 
to 24 year olds were believed to have contact with a TYA- 
PTC.16 Place of care was therefore directed by clinicians 
based on cancer type and geographical location. While 
there is an international mobilisation to implement 
specialist TYA services,12 including in other European 
countries, Australasia and North America, the impact of 
such services on clinical outcomes has not been robustly 
evaluated.
The BRIGHTLIGHT study is a prospective evaluation 
of the benefits of specialist TYA services in the English 
NHS. In order to capture the complexity of the delivery 
of TYA cancer care, it comprised an evaluation from 
the perspective of the environment of care,17 the work-
force delivering care18 and young people receiving care. 
BRIGHTLIGHT was developed with extensive input from 
young people as well as health professionals6 9 19 and 
based on consultation with young people.20 This included 
input into the selection of the primary outcome: quality 
of life (QOL).
Quality of life is defined as ‘…subjective, multidimen-
sional and dynamic. It is unique to each individual and 
includes aspects of physical, psychological and social 
function. It is dependent not only on the stage of devel-
opment but also the illness trajectory. This involves the 
achievement of goals and aspirations and the constraints 
imposed through ill health and treatment’.21 Measure-
ment of QOL uses the patient’s own report to evaluate 
the spectrum of impact of illness on them and has 
become an increasingly valued healthcare outcome. 
Previous reports of young people’s QOL after a cancer 
diagnosis have shown this to be significantly lower than 
normative population data.22 Longitudinal assessment 
has indicated QOL improved in the first year after diag-
nosis but there was no significant improvement in the 
second year.23 No evaluation beyond the second year 
has been reported and while studies have investigated 
predictors of QOL there has been no evaluation of the 
impact of different models of delivery of care on QOL. 
We examined QOL at 6, 12, 18, 24 and 36 months after 
diagnosis in relation to the amount of care young people 
received in a TYA- PTC.
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The BRIGHTLIGHT study is a mixed methods programme 
of research. Results from an embedded longitudinal 
cohort study, obtaining data from young people through 
a bespoke survey,24 are reported here. The survey was 
administered at five time points during the first 3 years 
after diagnosis (6, 12, 18, 24 and 36 months, waves 1 to 5 
respectively). A scale was developed, previously described 
in detail,25 using Hospital Episode Statistics (HES) inpa-
tient data to measure episodes of care in different NHS 
Trusts and then used to assign young people to one of 
three categories of TYA care dependent on how much 
inpatient HES activity recorded in the first 12 months 
after diagnosis was delivered in a TYA- PTC: no care in a 
TYA- PTC, that is, all care was delivered in a children’s or 
adult cancer unit (NO- TYA- PTC), some care delivered in 
a TYA- PTC with additional care in a children’s or adult 
cancer unit (SOME- TYA- PTC) or all care delivered in a 
TYA- PTC (ALL- TYA- PTC).
Patient and public involvement
BRIGHTLIGHT has been developed with young people 
from the point of inception and our Young Advisory 
Panel (YAP) have been involved in the management, 
implementation and dissemination of the study. This has 
been reported in detail previously20 26–29 but in summary, 
BRIGHTLIGHT was developed based on consultation 
with young people attending a patient conference in 2008: 
place of care was identified as the third priority for future 
research. Young people worked with the research team 
to conduct the research informing the National Institute 
for Health Research grant application6 including repre-
sentation as a co- applicant. The YAP have advised on 
changes to recruitment,28 helped develop the retention 
strategy,26 informed additional studies29 and are involved 
in dissemination.30
Participants and setting
BRIGHTLIGHT was open to recruitment between 
October 2012 and April 2015 in 109 English NHS hospi-
tals of which 97 recruited at least one young person. 
Eligibility was defined as aged 13 to 24 years at the 
time of diagnosis, newly diagnosed with cancer (ICD-10 
(International Classification of Diseases, 10th Revision) 
codes C00- C97) and recruited within 4 months of diag-
nosis. There was no eligibility exclusion for a language 
or sensory impairment affecting communication. The 
following groups were excluded: those serving a custodial 
sentence; not anticipated to be alive at the first point of 
data collection (6 months after diagnosis); or incapable 
of completing a survey. Details of the recruitment process 
are reported elsewhere.25 31 Young people gave written 
consent and parental consent was also obtained for those 
less than 16 years. Checks were made through the Demo-
graphic Batch Service at NHS digital before each wave of 
data collection to ensure young people were alive and to 
obtain their most recent address.
The sample size calculation was based on a compar-
ison between the three categoriesof TYA care25 for the 
primary outcome of PedsQL (Paediatric Quality of Life 
Questionnaire) total score,32 measured at five time points 
over the 3- year follow- up. Previously reported PedsQL 
data for childhood patients with cancer suggested a SD 
for this score of 16.33 To detect a difference in scores of 
eight units with 80% power34 required a sample of 200 
young people. This calculation assumed a significance 
level of 0.01 (two- sided) to allow for multiple compari-
sons between three categories of TYA care and assumed 
an average of three repeated measurements per patient 
(intracluster correlation 0.3 suggested as a maximum 
for similar patient outcomes35). The calculation allowed 
for adjustment for confounding factors using a variance 
inflation factor with a correlation of 0.5.36 To ensure 
adequate power to examine the effect of TYA care on 
QOL within subgroups of age at diagnosis (13 to 18 and 
19 to 24 years) and type of tumour (haematological and 
solid tumour groups), the minimum required sample size 
was raised to 800 (80% power).
Data collection
Data were collected from three sources: young people’s 
self- report, patient clinical records and NHS and Public 
Health England databases. Details of these data sources 
are reported elsewhere.25 Data presented here are 
responses to the BRIGHTLIGHT Survey, a bespoke survey 
containing five validated questionnaires and 169 descrip-
tive questions related to post diagnosis experience. The 
survey was administered through face- to- face interviews 
in young people’s homes by an independent research 
company at the first time point and either online or tele-
phone interview at subsequent waves of data collection.24
This paper reports data for the primary outcome, QOL, 
which was measured using the PedsQL.32 At the time of 
study development this was the only measure of QOL vali-
dated for TYA.37 It contains 23 items rated using a 5- point 
Likert Scale (never, almost never, sometimes, often and 
almost always). Responses are presented as four domain 
scores (physical, emotional, social and work/studies func-
tioning), two summary scores (physical and psychosocial 
function) and a total score. Domain, summary and total 
scores range from 0 to 100, with 100 representing the best 
possible QOL.
Analysis
Analysis was carried out following a predefined statistical 
analysis plan using Stata V.15. A mixed effects model was 
used to investigate the relationship between the catego-
ries of TYA care and the PedsQL total score, allowing for 
repeated measurements taken over the 3 years since diag-
nosis. The model was adjusted for confounding factors 
identified based on the conceptual model underpinning 
the BRIGHTLIGHT Survey6 24 and using a causal diagram 
in the form of a Directed Acyclic Graph (DAG) (DAGitty 
software www. dagitty. net; online supplemental figure 
1). Factors adjusted for were age at diagnosis, type of 
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cancer (leukaemia, lymphoma, brain and central nervous 
system, bone tumours, sarcoma, germ cell, melanoma, 
carcinomas and other), socioeconomic status (Index of 
Multiple Deprivation38 quintile), severity of cancer (least, 
intermediate and most25), ethnicity (white and other), 
choice offered about where to receive treatment (yes/no), 
presence of any long- term condition prior to cancer (yes/
no), days from first symptom to diagnosis and number of 
general practitioner visits before diagnosis. Geographical 
location (specified as 12 cities, derived from the TYA- PTC 
and their network of hospitals) was included in the model 
as a random effect. Models were extended to include 
interaction terms to investigate predefined subgroup 
effects by age at diagnosis (both as a continuous factor 
and using categories of 13 to 18 and 19 to 24 years) and 
tumour type (haematological and solid tumours). An 
interaction with time since diagnosis was also examined 
to investigate whether the relationship betweencategory 
of TYA care and QOL changed over time. Similar models 
were fitted for the PedsQL domain scores for physical, 
social, emotional and work/school/college functioning, 
and the psychosocial summary score.
The extent and patterns of missing QOL data over 
time were examined using summary statistics and profile 
plots. As there is no provision in the scoring of PedsQL 
to directly account for death, our main analysis did not 
distinguish between data ‘missing’ following death and 
that missing for other reasons. With the possibility of 
informative missing data due to deaths, a sensitivity anal-
ysis was carried where joint mixed- effect models for the 
longitudinal QOL scores and time until death were fitted 
to account for the correlation between the QOL and 
survival outcomes.39 The QOL estimates for the effect 
of category of TYA care were then compared with those 
obtained from previously fitted mixed models.
RESULTS
A total of 1126 young people were recruited. BRIGHT-
LIGHT survey data at wave 1 were available for 830 
(75%) participants and details of numbers at each wave 
are summarised in figure 1. Characteristics of those who 
did and did not complete wave 1 were similar, except 
for a higher proportion of non- white participants not 
completing wave 1 (12% vs 19%, p=0.004).25 Forty- eight 
participants could not be assigned acategory of TYA- 
PTC care as there were no linked HES inpatient records 
available. Data from 782 young people were therefore 
included. There were fewer young people receiving ALL- 
TYA- PTC care (n=193; 25%) in comparison to SOME- 
TYA- PTC (n=312; 40%) and NO- TYA- PTC (n=277; 35%). 
Demographic characteristics and summary of variables 
adjusted for in the analysis are shown in table 1. Young 
people who received NO- TYA- PTC care were slightly 
older, more likely to be working full- time/part- time, had 
less severe disease, had a better prognosis and were more 
likely to have been given a choice in their place of care. 
Young people who had ALL- TYA- PTC care were more 
likely to come from less deprived areas.
Longitudinal changes in the average QOL total score 
according to the category of care are shown in figure 2 
(summary by wave is given in online supplemental table 
1). Across all time periods this illustrates lower QOL score 
for those in the SOME- TYA- PTC and ALL- TYA- PTC groups 
compared with the NO- TYA- PTC group. Differences 
between the category of care appeared to diminish steadily 
over time. The negative coefficients for categories of care 
from the model indicate that across the 3- year period of the 
study QOL scores were on average higher for those with 
NO- TYA- PTC care compared with SOME- TYA- PTC and 
ALL- TYA- PTC with a larger difference compared with the 
SOME- TYA- PTC category (table 2). The differences were 
statistically significant but fell inside the threshold of eight 
points proposed to be clinically significant.32 There was no 
evidence that the relationship between QOL and category 
of care was different for the combined group of leukaemia/
lymphomas compared with other cancers. Also, there was 
no evidence of a difference by age at diagnosis (figure 3). 
There was evidence that the QOL/category of care relation-
ship changed over time such that differences between the 
groups diminished, that is, slopes for SOME- TYA- PTC and 
ALL- TYA- PTC over time are steeper than for NO- TYA- PTC, 
Figure 1 Participation at each wave of data collection. 
*Drop- outs between waves due to death, permanent opt- out 
or wave opt- out. Wave opt- outs prior to being issued were 
not permanent opt- outs; participants could opt- out of a 
single wave but participate in subsequent waves; these cases 
were not removed from the cohort permanently.
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Table 1 Participant characteristics according to category of care at wave 1








Age at diagnosis (years) Mean (SD) 21.04 (3.01) 19.40 (3.41) 19.97 (3.15)
Age groups 13 to 15 years 37 (10%) 72 (17%) 40 (15%)
16 to 18 years 34 (10%) 128 (31%) 78 (29%)
19 to 24 years 288 (80%) 215 (52%) 152 (56%)
Gender Male 148 (53%) 165 (53%) 112 (58%)
Female 129 (47%) 147 (47%) 81 (42%)
Ethnicity* White 252 (91%) 273 (88%) 163 (84%)
Mixed 4 (1%) 5 (2%) 4 (2%)
Asian 15 (5%) 24 (8%) 20 (10%)
Black 4 (1%) 7 (2%) 2 (1%)
Other 2 (1%) 3 (1%) 4 (2%)
Socioeconomic status 
(IMD quintile)
1 – most deprived 66 (24%) 73 (24%) 34 (18%)
2 47 (17%) 52 (17%) 32 (17%)
3 51 (19%) 60 (20%) 37 (20%)
4 65 (24%) 61 (20%) 40 (21%)
5 – least deprived 46 (17%) 59 (19%) 46 (24%)
Marital Status Married/civil partnership 9 (4%) 8 (3%) 6 (3%)
Cohabiting 43 (17%) 27 (10%) 18 (10%)
Single/divorced 198 (79%) 227 (87%) 148 (86%)
Current status Working full- time/part- time 126 (45%) 72 (23%) 43 (22%)
In education 61 (22%) 112 (36%) 81 (42%)
Other work (apprentice/intern/
voluntary)
6 (2%) 5 (2%) 6 (3%)
Unemployed 10 (4%) 11 (4%) 7 (4%)
Long- term sick 39 (14%) 51 (16%) 31 (16%)
Not seeking work 35 (13%) 61 (20%) 25 (13%)
Type of cancer (Birch 
classification)
Leukaemia 19 (7%) 49 (16%) 33 (17%)
Lymphoma 111 (40%) 75 (24%) 70 (36%)
CNS 9 (3%) 9 (3%) 12 (6%)
Bone 7 (3%) 59 (19%) 3 (2%)
Sarcomas 8 (3%) 31 (10%) 15 (8%)
Germ cell 64 (19%) 55 (18%) 31 (16%)
Skin 22 (8%) 1 (<1%) 4 (2%)
Carcinomas (not skin) 41 (15%) 31 (10%) 23 (12%)
Miscellaneous specified† 5 (2%) 2 (<1%) 1 (<1%)
Unspecified malignant 1 (<1%) 0 1 (<1%)
Severity at diagnosis   
(row %, column %) Least 200 (46% to 72%) 133 (31% to 43%) 95 (22% to 49%)
Intermediate 49 (26% to 18%) 82 (44% to 26%) 56 (30% to 29%)
Most 28 (17% to 10%) 97 (58% to 31%) 42 (25% to 22%)
Prognostic score <50% 21 (8%) 60 (19%) 41 (21%)
50% to 80% 54 (20%) 125 (40%) 44 (23%)
>80% 200 (73%) 126 (41%) 108 (56%)
Continued
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therefore rates of improvement of QOL were superior in 
the ALL- TYA- PTC and SOME- TYA- PTC (table 3), mirroring 
what was seen in figure 2.
Analysis of the physical functioning and work/school/
college functioning domain scores showed a similar 
pattern to that seen for the total QOL score. The SOME- 
TYA- PTC group had a mean difference in physical func-
tioning of −8.28 compared with the NO- TYA- PTC group, 
which was statistically significant and above the threshold 
for clinical significance. For the emotional functioning 
domain however, difference between groups were less 
marked and notably the average difference in scores 
between the SOME- TYA- PTC and NO- TYA- PTC was 
reduced. Difference between groups in terms of social 
functioning and the psychosocial summary scores were 
small and not statistically significant (figures 4–8, table 2).
Results from post- hoc analysis excluding patients 
with bone tumours were similar to those for all cancers 
combined (see online supplemental table 2). A subgroup 
investigation of patients with lymphoma, the biggest 
diagnostic category, showed these were not significantly 
different from those for the group of other cancer types 
(see online supplemental table 3). Finally, sensitivity anal-
yses using joint modelling for survival alongside longi-
tudinal QOL did not alter the conclusion based on the 
main results (see online supplemental table 4).
DISCUSSION
Our study is the first reported national longitudinal eval-
uation of specialist cancer services, more specifically TYA- 
PTCs and their networks of care, as they were originally 








Location‡ Birmingham 41 (15%) 59 (19%) 12 (6%)
Bristol 51 (18%) 32 (10%) 4 (2%)
Cambridge 12 (4%) 8 (3%) 1 (1%)
Manchester 22 (8%) 35 (11%) 11 (6%)
Merseyside 13 (5%) 11 (4%) 6 (3%)
East Midlands 15 (5%) 24 (8%) 60 (31%)
Leeds 20 (7%) 25 (8%) 25 (13%)
Newcastle 13 (5%) 6 (2%) 24 (12%)
Oxford 5 (2%) 4 (1%) 7 (4%)
London 60 (22%) 83 (27%) 10 (5%)
Sheffield 7 (3%) 9 (3%) 9 (5%)
Southampton 18 (7%) 16 (5%) 24 (12%)
Given a choice about 
where to receive 
treatment§
  n=272 n=311 n=192
Yes 121 (45%) 86 (28%) 48 (25%)
No (or <19 years) 151 (56%) 225 (72%) 144 (75%)
Long- term condition 
prior to cancer
n=277 n=311 n=193
Yes 20 (7%) 34 (11%) 18 (9%)
No 257 (93%) 277 (89%) 175 (91%)
Time to diagnosis: days 
from first symptom
Median (IQR), (min, max) n=264 n=304 n=188
62 (29.5 to 168.5)
(0 to 1340)
65.5 (29.5 to 152.5)
(0 to 959)
63.5 (25.5 to 151.0)
(0 to 1217)
Time to diagnosis: 
number of GP visits 
before diagnosis
Median (IQR), (min, max) n=274 n=311 n=193
1 (0 to 3)
(0 to 20)
1 (0 to 3)
(0 to 20)
2 (1 to 3)
(0 to 40)
*Wave 1 data was used with missing values completed using available Public Health England data.
†Includes 4 ‘unclassified’ – treated in cancer unit but did not have cancer
‡Those <19 years at diagnosis were assumed not to have been given a choice
§Includes the TYA- PTC and hospitals linked to the multidisciplinary team at the TYA- PTC; where available based on hospital of diagnosis, for 
77 cases based on recruiting hospital
CNS, central nervous system; GP, general practitioner; IMD, index of multiple deprivation; TYA, teenagers and young adults; TYA- PTC, TYA 
principal treatment centres.
Table 1 Continued
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defined in 2005.3 We recorded patient outcomes to deter-
mine the influence of place of care, and after consulta-
tion with patients and professionals, selected QOL as the 
primary parameter of interest. Using routinely collected 
hospital admission data to identify time spent in the 
TYA- PTC, we categorised patients by care received in the 
TYA- PTC (all, none or some). We found that there was 
a statistically significant difference between these groups 
with those in the NO- TYA- PTC group having superior 
QOL compared with those in the ALL- TYA- PTC group, 
Figure 2 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) total score over time since diagnosis (with 
95% CIs). Graph based on data collected in Waves 1 to 5, 
plotted against median time since diagnosis. TYA, teenagers 
and young adults; TYA- PTC, TYA principal treatment centres.
Table 2 Mixed model investigating the relationship between categories of TYA care received during the first 12 months from 
diagnosis and total quality of life and domain scores over 3 years (n=733)
Difference in means 95% CI P value†
Total quality of life score (n=733)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −5.63 −8.49 to −2.77 p=0.0005
ALL- TYA- PTC −4.17 −7.28 to −1.07
Physical functioning (n=733)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −8.28 −11.95 to −4.61 p=0.0001
ALL- TYA- PTC −4.79 −8.76 to −0.81
Emotional functioning (n=733)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −4.29 −7.79 to −0.80 p=0.015
ALL- TYA- PTC −5.43 −9.29 to −1.57
Social functioning (n=733)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −2.96 −5.77 to −0.16 p=0.099
ALL- TYA- PTC −2.49 −5.60 to 0.62
Work/school/college functioning (n=595)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −6.87 −10.45 to −3.30 p=0.0007
ALL- TYA- PTC −4.67 −8.47 to −0.87
Psychosocial summary score (n=600)
  TYA care category (v NO- TYA- PTC) SOME- TYA- PTC −2.51 −5.71 to 0.70 p=0.074
ALL- TYA- PTC −3.96 −7.44 to −0.48
*Results from a three category of care model for repeated measurements of quality of life over time since diagnosis, with a random effect 
for geography and adjustment for time since diagnosis, age at diagnosis, type of cancer, socioeconomic status, severity of cancer, ethnicity, 
choice about where to receive treatment, long- term condition prior to cancer, days from first symptom to diagnosis, number of general 
practitioner visits before diagnosis. Missing data for 96 due to missing TYA category and missing data in other covariates.
†Likelihood ratio test.
TYA, teenagers and young adults; TYA- PTC, TYA principal treatment centres.
Figure 3 Subgroup investigations for cancer type 
(leukaemia/lymphoma v other) and age group (<19 v 
19+): Results from adjusted* random effects models with 
interaction terms (n=733). *Model with a random effect 
for city and adjustment for time since diagnosis, age at 
diagnosis, type of cancer, socioeconomic status, severity of 
cancer, ethnicity, choice about where to receive treatment, 
long- term condition prior to cancer, days from first symptom 
to diagnosis, number of general practitioner visits before 
diagnosis. v, versus.
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while those in the SOME- TYA- PTC group reported lowest 
QOL. Quality of life improved over time in all three 
groups, but rates of improvement were significantly better 
for SOME- TYA- PTC and ALL- TYA- PTC.
We predicted that sociodemographic or disease factors 
might explain some of the differences between groups 
and adjusted the analyses for these confounding variables. 
Despite extensive analysis we were unable to identify 
other factors to account for these differences. Like other 
reports of young people’s QOL after a cancer diagnosis,22 
we found this to be low, irrespective of where young 
people were treated. We found that young people who 
did not access a TYA- PTC had better QOL in comparison 
to those who had all or some of their care in a TYA- PTC. 
However, while this was statistically significant, the mean 
difference between the NO- TYA- PTC and ALL- TYA- PTC 
groups was not at a level proposed as clinically significant 
(eight- point difference33). Nevertheless, it is important 
to consider reasons for lower QOL when young people 
experience multiple types of place of care and the deter-
minants of place of care. Based on work in other settings 
where care is delivered on multiple sites40 we surmise that 
this may result from limited coordination of care, perhaps 
including inadequate communication with and between 
professionals. Having to repeat conversations and expla-
nations of their cancer diagnosis and treatment details 
is frequently reported as burdensome to young people.6 
A greater understanding of the determinants of place of 
care for young people and the factors which influence a 
sense of care coordination deserve further exploration.
It is interesting that young people who had no access 
to the TYA- PTC rated their QOL the highest. This could 
reflect young people rating themselves by comparison 
with the other people they could see being treated for 
cancer outside of a TYA- PTC, including older adults. It 
could also be that young people chose to receive care 
locally rather than travel to the TYA- PTC so they could 
keep their links to their ‘normal’ life, which is supported 
by the domain level analysis where they also rated their 
work/school/college functioning higher. Alternatively, 
the strong emphasis placed on the unique issues faced by 
TYA with cancer by members of the TYA MDT staff may 
have heightened patients’ awareness of these problems in 
comparison to the NO- TYA- PTC group, and consequently 
Table 3 Investigation of changes in QOL score over time: results from adjusted mixed effects models with interaction term 
(time months x TYA- PTC category). Coefficients for time describe the linear increase in QOL score per month within each TYA 
care category (n=733)
TYA care category Coefficient for time (per month) 95% CI P value from interaction
NO- TYA- PTC 0.26 0.18 to 0.34 0.004
SOME- TYA- PTC 0.45 0.37 to 0.53
ALL- TYA- PTC 0.37 0.27 to 0.46
Model with a random effect for city and adjustment for time since diagnosis, age at diagnosis, type of cancer, socioeconomic status, severity 
of cancer, ethnicity, choice about where to receive treatment, long- term condition prior to cancer, days from first symptom to diagnosis, 
number of general practitioner visits before diagnosis.
QOL, quality of life; TYA, teenagers and young adults; TYA- PTC, TYA principal treatment centres.
Figure 4 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) physical functioning domain scores over 
time since diagnosis (with 95% CIs). (Graphs based on data 
collected in Waves 1 to 5, plotted against median time since 
diagnosis).TYA, teenagers and young adults; TYA- PTC, TYA 
principal treatment centres.
Figure 5 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) emotional functioning domain scores over 
time since diagnosis (with 95% CIs). (Graphs based on data 
collected in Waves 1 to 5, plotted against median time since 
diagnosis). TYA, teenagers and young adults; TYA- PTC, TYA 
principal treatment centres.
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they lowered their perception of their QOL while the 
NO- TYA- PTC group remained comparatively unaware of 
such concerns. Future work could focus on the influence 
of being given a choice in the place where young people 
receive care, and the factors that young people consider 
to be important when making this decision.
The longest follow- up for longitudinal assessment of 
QOL previously reported to 2 years after diagnosis,23 
which showed no improvement after the first year. 
However, we found that there was a gradual improvement 
in QOL over 3 years, which was more rapid when young 
people received all their care in a TYA- PTC. The philos-
ophy of TYA cancer care includes the delivery of care to 
support young people to achieve their long- term personal 
outcomes (education, employment and relationships), 
the benefits of care provided by the TYA- PTC may there-
fore not be realised in the short- term. It would be bene-
ficial for us to understand whether this improvement 
continued into long- term survivorship, especially the 
influence of QOL reaching and sustaining goals such as 
employment.
There are several limitations to this study including how 
specialist care was defined and measured. This was based 
on the location of the 13 NHS Trusts in England commis-
sioned as TYA- PTCs but not the specific hospitals within 
these Trusts where the specialist TYA services were based. 
For example, a Trust which included multiple hospitals 
could only have specialist TYA services in one therefore 
a young person receiving care in one of the other hospi-
tals was assumed to have had access to specialist TYA 
services, that is, they were assigned to the ALL- TYA- PTC 
group rather than NO- TYA- PTC. Furthermore, using the 
Trust commissioned as a TYA- PTC does not capture the 
details of the TYA- specific care available or delivered and 
assumes that this is equal in all. We know there was wide 
variation in the delivery of care through the duration of 
the study.41 However, at the time of study inception HES 
was the sole data source available that would allow an 
objective measurement of place of care. In complemen-
tary work, the key elements of specialist age- appropriate 
care for TYA have been described.17 This would provide 
an alternative categorisation against which to measure 
patient and clinical outcomes.
The cohort represented approximately a fifth of the 
total cancer population diagnosed between July 2012 
and December 2014 as ascertained through the National 
Cancer Registration and Analysis Service, and there were 
differences in cancer types between the cohort and those 
not recruited,25 which could impact on the generalisability 
of the results. For example, the cohort included a higher 
proportion of young people with germ cell tumours and 
lymphoma, but a lower proportion of carcinoma and 
Figure 6 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) social functioning domain scores over time 
since diagnosis (with 95% CIs). (Graphs based on data 
collected in Waves 1 to 5, plotted against median time since 
diagnosis). TYA, teenagers and young adults; TYA- PTC, TYA 
principal treatment centres.
Figure 7 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) work/school/college functioning domain 
scores over time since diagnosis (with 95% CIs). (Graphs 
based on data collected in Waves 1 to 5, plotted against 
median time since diagnosis). TYA, teenagers and young 
adults; TYA- PTC, TYA principal treatment centres.
Figure 8 Mean PedsQL (Paediatric Quality of Life 
Questionnaire) psychosocial summary score scores over 
time since diagnosis (with 95% CIs). (Graphs based on data 
collected in Waves 1 to 5, plotted against median time since 
diagnosis).
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skin cancers. We used a single mode of survey admin-
istration at wave 1, and multiple modes at waves 2 to 5. 
While this may have introduced a social desirability bias 
(noted to be more so for telephone interviews than web- 
based surveys42), this was to increase the response rate as 
work during the feasibility study for BRIGHTLIGHT indi-
cated no one method was acceptable to all young people. 
Finally, we used a measure of QOL that was validated 
across the age 13 to 24 years,37 but this may not reflect 
the issues that were most relevant to young people with 
cancer in the UK (having been developed in the USA in a 
non- cancer population). This is supported by comments 
made in the cognitive interviews undertaken when the 
survey was being developed; young people did not agree 
with the wording of the school functioning domain, so 
this was changed to work/school/college.24 However, 
young people who were not in education, employment 
or training would not be able to answer these questions. 
Future work is required to develop TYA- specific QOL 
measures that reflect issues specific to this population.
Despite these limitations this is the first systematic 
prospective evaluation of specialist services for young 
people with cancer. We have found that TYA cancer care 
as commissioned in 2010 resulted in young people’s 
QOL gradually improving 3 years after diagnosis and 
improving more rapidly from a lower baseline if young 
people’s treatment involved a TYA- PTC. NHS care path-
ways may result in care in specialist centres for young 
people with the poorest initial QOL, and local care for 
those with the least poor initial QOL, risk stratifying the 
patients appropriately. Young people who receive some 
care in both a children’s or adult cancer unit and at a 
TYA- PTC also have an improvement in QOL, but the rate 
of improvement was less and QOL remained lower than 
for young people treated in a single type of organisation. 
The factors influencing place of care and the differences 
in QOL and survival remain unclear. A model of ‘joint 
care’, increasing the emphasis and investment in commu-
nication between TYA- PTCs and other Trusts designated 
to deliver elements of TYA cancer care, is currently 
proposed by the NHS in England. The influence of such 
changes in care provision should be examined prospec-
tively in future to identify if QOL of young people with 
cancer is improved wherever care is received.
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